EXECUTIVE ENGAGEMENTS
POOL
3682
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
662
Interactions with Platform & by Email
PARTICIPANTS
112
Unique # Participated
VALIDATIONS
32
Responses Validated*
COMPANIES
46
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
196
EDITION
8
PRICE
USD 4950
CODE
MCP16141
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.6 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 8.9% over the analysis period 2020-2027. Augmentation Therapy, one of the segments analyzed in the report, is projected to record a 9.7% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Bronchodilator segment is readjusted to a revised 9.4% CAGR for the next 7-year period.
The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$463.6 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$493.1 Million by the year 2027 trailing a CAGR of 8.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.
In the global Corticosteroids segment, USA, Canada, Japan, China and Europe will drive the 7.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$189.6 Million in the year 2020 will reach a projected size of US$319.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$328.4 Million by the year 2027.
SELECT PLAYERS
Abeona Therapeutics Inc.; Applied Genetic Technologies Corporation; Arrowhead Pharmaceuticals Inc.; AstraZeneca PLC; Baxter International, Inc.; Biogen, Inc.; Boehringer Ingelheim International GmbH; Chiesi Farmaceutici SpA; CSL Behring; Curaxys; GlaxoSmithKline PLC; Grifols International SA; Kamada Ltd.; Pfizer, Inc.; ProBioGen AG; ProMetic Life Sciences, Inc.; Shire PLC; Teva Pharmaceutical Industries Ltd.
SEGMENTS
» End-Use (Specialty Clinics, Hospitals, Pharmacies) » Route of Administration (Parenteral, Inhalation, Oral) » Treatment (Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, Other Treatments)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Augmentation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Bronchodilator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oxygen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| China Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| France Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Treatment - Percentage Breakdown of Value Sales for Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy and Other Treatments for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Specialty Clinics, Hospitals and Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by End-Use - Percentage Breakdown of Value Sales for Specialty Clinics, Hospitals and Pharmacies for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Parenteral, Inhalation and Oral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Inhalation and Oral for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 46 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com